rapid-acting insulin product NovoLog, for the improvement of glycemic control in adults and children with diabetes mellitus. The FDA approved 3 mL single-patient-use prefilled pen and 10 mL ...

Insulin-aspart-szjj is the first rapid-acting insulin biosimilar approved and the third insulin product approved by the FDA.

Merilog will be provided by prefilled pen in a 3 mL dose or in a multiple ... Novo Nordisk announced a planned 75% reduction in the cost of NovoLog. Then a few days later, Sanofi followed suit ...

NovoLog is also available in pen injector formats. Before Merilog, the FDA has given the go-ahead to two biosimilars of Sanofi's basal insulin product Lantus (insulin glargine) – Viatris ...

FDA drug alerts in endocrinology, including drug approvals, drug warnings, FDA medical device recalls, and FDA drug label ...

The US Food and Drug Administration has approved Merilog (insulin-aspart-szjj) as a biosimilar to Novolog (insulin aspart) for adults and pediatric patients with diabetes mellitus.

Merilog — like Novolog — should be administered 5 to ... Semglee is $27.77 while for Lantus it is $35 for a box of five pens. At least in this community, we would all agree that insulin ...

Both a 3-mL single-patient-use prefilled pen and a 10-mL multiple-dose vial are included in this approval. Serious side effects reported with Merilog include hypoglycemia, severe allergic ...

Like Novolog, Merilog should be administered within ... According to MSF, data published in JAMA Network Open shows that insulin pens could be produced for as little as $0.94 per unit and remain ...